Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1976 1
1977 1
1979 1
1980 2
1981 3
1982 4
1983 6
1984 6
1985 5
1986 4
1987 13
1988 18
1989 17
1990 8
1991 15
1992 11
1993 3
1994 7
1995 6
1996 10
1997 6
1998 9
1999 2
2000 15
2001 9
2002 9
2003 13
2004 4
2005 10
2006 12
2007 17
2008 4
2009 10
2010 11
2011 10
2012 9
2013 10
2014 11
2015 7
2016 5
2017 7
2018 12
2019 1
2020 5
2021 2
2022 3
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Results by year

Filters applied: . Clear all
Page 1
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Mitsudomi T, et al. Among authors: negoro s. Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18. Lancet Oncol. 2010. PMID: 20022809 Clinical Trial.
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Ohe Y, et al. Among authors: negoro s. Ann Oncol. 2007 Feb;18(2):317-23. doi: 10.1093/annonc/mdl377. Epub 2006 Nov 1. Ann Oncol. 2007. PMID: 17079694 Free article. Clinical Trial.
Biodegradation of nylon oligomers.
Negoro S. Negoro S. Appl Microbiol Biotechnol. 2000 Oct;54(4):461-6. doi: 10.1007/s002530000434. Appl Microbiol Biotechnol. 2000. PMID: 11092619 Review.
[Nogitecan hydrochloride].
Negoro S. Negoro S. Nihon Rinsho. 2002 May;60 Suppl 5:370-3. Nihon Rinsho. 2002. PMID: 12101691 Review. Japanese. No abstract available.
Irinotecan in small-cell lung cancer--Japanese trials.
Fukuoka M, Masuda N, Kudoh S, Negoro S. Fukuoka M, et al. Among authors: negoro s. Oncology (Williston Park). 2000 Jul;14(7 Suppl 5):57-62. Oncology (Williston Park). 2000. PMID: 10981292 Review.
Structural and functional characterization of nylon hydrolases.
Negoro S, Kato DI, Ohki T, Yasuhira K, Kawashima Y, Nagai K, Takeo M, Shibata N, Kamiya K, Shigeta Y. Negoro S, et al. Methods Enzymol. 2021;648:357-389. doi: 10.1016/bs.mie.2020.11.004. Epub 2020 Dec 29. Methods Enzymol. 2021. PMID: 33579412
[Treatment of small cell lung cancer].
Negoro S. Negoro S. Gan To Kagaku Ryoho. 2005 Jun;32(6):777-82. Gan To Kagaku Ryoho. 2005. PMID: 15984515 Review. Japanese.
337 results